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ATP-binding cassette transporters A1 and G1
Receptor-interacting protein 140Receptor-interacting protein 140 (RIP140) is a multifunctional coregulator of lipid metabolism and
inﬂammation. However, the potential role of RIP140 in atherosclerosis remains unknown. The
present study investigated the impact of RIP140 on foam cell formation, a critical step in pathogenesis
of atherosclerosis. The expression of RIP140 was increased in foam cells. RIP140 overexpression
resulted in decreased cholesterol efﬂux in macrophages and their concomitant differentiation into
foam cells. Moreover, RIP140 negatively regulated the macrophage expression of ATP-binding
cassette transporters A1 and G1 (ABCA1/G1), by suppressing the expression and activity of liver X recep-
tor (LXR). These ﬁndings shed light onto the contribution of RIP140 to the development and progression
of atherosclerosis, and suggest a novel therapeutic target for the treatment of atherosclerosis.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction macrophages is crucial to prevent lipid overload, and ultimately,It is now generally accepted that atherosclerosis is a disorder of
lipid metabolism as well as a chronic inﬂammatory disease [1,2].
Cholesterol homeostasis in macrophages is of critical importance
because these cells have a pivotal function in the vessel wall and
in the development of atherosclerotic lesions [3,4]. In reality, the
modiﬁed lipoproteins scavenged by macrophages are processed,
stored and progressively accumulated in cytoplasmic droplets,
which leading to the formation of foam cells and the progression
of early to intermediate atherosclerotic lesions [5]. Therefore,
maintaining the balance of cholesterol uptake and efﬂux inthe progression of atherosclerosis. A group of scavenger receptors,
including scavenger receptor class A (SR-A) and cluster of differen-
tiation 36 (CD36), are mainly responsible for the internalization of
oxidized LDL (oxLDL) and promote cholesterol accumulation in
macrophages [6–8]. On the contrary, the efﬂux of intracellular cho-
lesterol is mediated by reverse cholesterol transporters, such as
scavenger receptor class B type I (SR-BI), ATP-binding membrane
cassette transport protein A1 (ABCA1) and G1 (ABCG1) [9–11] .
Receptor-interacting protein 140 (RIP140) has been deﬁned as a
multifunctional coregulator following its recruitment to nuclear
receptors aswell as target genes [12]. It’s capable of interactingwith
anumberof ligandboundnuclear receptors suchasperoxisomepro-
liferator-activated receptors (PPARs), liver X receptor (LXR), and
estrogen receptor-related receptor (ERR), particularly important in
modulating lipid and glucose metabolism [13]. In adipocytes,
RIP140 can affect lipid droplet formation indirectly by downregulat-
ing the expression of cell death-inducing DNA fragmentation factor-
a-like effector A (CIDEA). In the liver, RIP140 acts as a coactivator
with LXR to promote the expression of sterol regulatory element
binding protein (SREBP) 1c and fatty acid synthase (FAS), which
promote TAG synthesis. Interestingly, it also acts as a corepressor
with LXR to inhibit gene expression of phosphoenolpyruvate
carboxykinase (PEPCK) to limit gluconeogenesis in hepatocytes
Fig. 1. Expression of RIP140 in foam cells. Differentiated THP-1 macrophages and RAW 264.7 were loaded with oxLDL (50 lg/ml) for 24 h. The mRNA and protein levels of
RIP140 were determined by quantitative real-time PCR (A) and Western blot (B), respectively. The results were normalized (mRNA by GAPDH and protein by a-tubulin) and
then presented as the fold of control. Data are expressed as means ± S.E.M. (n = 3). ⁄P < 0.05, ⁄⁄P < 0.01 vs. control.
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ciate with NF-jB in macrophages and cardiomyocytes to coactivate
proinﬂammatory cytokine production [15,16].
In view of the critical role of RIP140 in lipogenesis and inﬂam-
matory, it is hypothesized that RIP140 may be involved in the
development and progression of atherosclerosis. The present study
was designed to investigate whether or not RIP140 participates in
the formation of macrophage foam cells. The expression of RIP140
in macrophage foam cells stimulated by oxLDL was examined.
RIP140 was overexpressed by recombinant adenovirus (Ad-
RIP140) in macrophages, and the effect of Ad-RIP140 on cholesterol
uptake and efﬂux was studied. Finally, the molecular mechanisms
of RIP140 in regulating cholesterol accumulationwere investigated.
2. Materials and methods
Rabbit polyclonal antibody RIP140 and anti-SR-A were pur-
chased from Abcam. Mouse anti-ABCA1 antibody was obtained
from Millipore (Billerica, MA, USA). Anti-ABCG1 and anti-LXRa
were purchased from ImmunoWay (Newark, DE). Anti-LXRb was
supplied by Proteintech Group (Chicago, IL, USA). Mouse anti-a-
tubulin, rabbit anti-histone H1 antibody, human apolipoprotein
A-I, phorbol 12-myristate 13-acetate (PMA), Oil Red O, 40,6-diami-
dino-2-phenylindole (DAPI), Harris hematoxylin and methyl-b-
cyclodextrin (substitution range is 10.5–14.7) were purchased
from Sigma–Aldrich (St. Louis, MO). Lipofectamine 2000 was
obtained from Invitrogen (Carlsbad, CA). LXR agonist T0901317
was from Enzo Biochem Inc (Switzerland). Human HDL and oxi-
dized LDL were obtained from Yiyuan Biotech (Guangzhou, CN).
BODIPY-cholesterol was supplied by Avanti Polar Lipids (Alabaster,
Alabama)
Additional materials and methods are listed in Supplementary
Materials. Data are expressed as means ± S.E.M. unless otherwise
speciﬁed. Statistical analyses were performed by two-tailed
unpaired Student’s t-test between two groups and by one-way
ANOVA followed by the Bonferroni post hoc test for multiple com-
parisons. The analyses were performed using GraphPad Prism 5.0
software (GraphPad Software Inc., La Jolla, CA). P < 0.05 was con-
sidered statistically signiﬁcant.
3. Results
3.1. Expression of RIP140 in foam cells
Since macrophage foam cells have been deﬁned as a critical fac-
tor in the development of atherosclerosis, we ﬁrst evaluated theexpression of RIP140 in macrophage foam cells stimulated by
oxLDL. As shown in Fig. 1, the mRNA and protein levels of
RIP140 were enhanced in both human THP-1 macrophages and
Raw 264.7 murine macrophages after oxLDL treatment, suggesting
that the upregulation of RIP140 may play a role in foam cell
formation.
3.2. Overexpression of RIP140 aggravates oxLDL-induced cholesterol
accumulation and attenuates cholesterol efﬂux in macrophages
To further investigate the effect of RIP140 on foam cell forma-
tion, particularly cholesterol accumulation, adenovirus expressing
RIP140 (Ad-RIP140) were constructed [17]. As shown in Fig. 2A,
protein level of RIP140 was enhanced by approximately 7-fold in
THP-1-derived macrophages infected with Ad-RIP140. Oil Red O
staining revealed that both RIP140 overexpressing and oxLDL
treatment signiﬁcantly accelerated intracellular lipid accumula-
tion, while the combination of Ad-RIP140 and oxLDL treatment
did not further increase intracellular lipids (Fig. 2B). In addition,
the cellular lipid accumulation was determined by confocal micro-
scope after incubation with the ﬂuorescent Dil-oxLDL for 4 h. As
shown in Fig. 2C, Ad-RIP140 signiﬁcantly augmented the intracel-
lular Dil-oxLDL as compared to Ad-GFP group. Moreover, choles-
terol efﬂux was evaluated by using BODIPY-cholesterol [18], and
the efﬁciency of apoAI- and HDL-mediated cholesterol efﬂux in
macrophages were markedly attenuated by Ad-RIP140 treatment
(Fig. 2D and E). Thus, these observations indicate that RIP140
may trigger the foam cell formation by aggravating cholesterol
accumulation and suppressing cholesterol efﬂux.
3.3. RIP140 reduces macrophage ABCA1/G1 expression
To explore the mechanism that RIP140 regulated cholesterol
accumulation, we examined the impacts of RIP140 on the expres-
sion of scavenger receptors such as SR-A and CD36 which are
responsible for cholesterol uptake [6,8], and cholesterol transport-
ers such as ABCA1 and ABCG1 which mediate cholesterol efﬂux
[10,11], in THP-1 macrophages. Compared to Ad-GFP group, Ad-
RIP140 decreased expression of ABCA1 and ABCG1, without affect-
ing SR-A and CD36 (Fig. 3A and B), indicating that RIP140 mainly
affects cholesterol efﬂux rather than cholesterol uptake. Notably,
in oxLDL-induced foam cells, expression of ABCA1/G1 were
signiﬁcantly enhanced, which were counteracted by RIP140 over-
expression (Fig. 3C). Therefore, these data imply that RIP140
impairs ABCA1/G1-mediated cholesterol efﬂux, which might con-
tribute to the formation of macrophage foam cells.
Fig. 2. RIP140 overexpression increases lipid accumulation and inhibits cholesterol efﬂux in macrophages. (A) Overexpressing RIP140 in THP-1-derived macrophages. Data
are expressed as means ± S.E.M. (n = 3). ⁄⁄⁄P < 0.001 vs. Ad-GFP. (B) THP-1 macrophages were co-treated with Ad-RIP140 and oxLDL (50 lg/ml) for 24 h. After incubation, cells
were ﬁxed and stained with Oil Red O. (C) THP-1 macrophages were infected with Ad-RIP140 or an empty vector for 24 h. The cells were then incubated with Dil-oxLDL
(10 lg/ml) for 4 h followed by washing twice with PBS. Cellular Dil-oxLDL was assessed by confocal microscopy. Data are means ± S.E.M. (n = 4). ⁄P < 0.05 vs. Ad-GFP. (D and
E) Macrophages were treated with Ad-RIP140 and DODIPY-cholesterol as described in Section 2. Cholesterol efﬂux was expressed as percentage ﬂuorescence in the medium
relative to total ﬂuorescence. Data are means ± S.E.M. (n = 3). ⁄P < 0.05 vs. control.
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repression of cholesterol efﬂux
ABCA1/G1 expression is tightly controlled by LXR activation
[19,20], which is due to the existence of an LXR response element
(LXRE) in both ABCA1 and ABCG1 genes. To investigate whether
LXR is involved in RIP140-induced ABCA1/G1 downregulation,
the nuclear expression of LXR in response to RIP140 overexpres-
sion was assessed. As shown in Fig. 4A, when exposed to Ad-
RIP140, the nuclear levels of LXRa but not LXRb, were substantially
decreased in the presence or absence of T0901317, a synthetic LXR
agonist.
Afterwards, Co-IP results revealed that there was an interaction
between RIP140 and LXR in macrophages (Fig. 4B). To further
evaluate the activation of ABCA1 promoter in response to
overexpressing RIP140, the ABCA1-promoter-luciferase reporter
were introduced into cells with or without RIP140 overexpression.Ad-RIP140 signiﬁcantly inhibited LXR transcriptional activity in
the presence or absence of T0901317 (Fig. 4C). Consistent with this,
in cells transfected with LXRa, overexpression of RIP140 also
remarkably inhibited the transcriptional activity of LXR (Fig. 4D).
Moreover, activation of LXR by T0901317 augmented the expres-
sion of ABCA1/G1. Overexpressing RIP140 abrogated the LXR-
induced increase in ABCA1/G1 protein level (Fig. 4E).
Taken together, these results imply that LXR is involved in the
regulation of ABCA1/G1 by RIP140. RIP140 abrogates the
expression of LXRa and decreases the transcriptional activity of
LXR, leading to a reduction of ABCA1/G1, which subsequently
impairs cholesterol efﬂux.
4. Discussion
Recently, growing importance of RIP140 in modulating metab-
olism and inﬂammation has been realized and accepted. Indeed,
Fig. 3. Effect of RIP140 on the expression of scavenger receptors and reverse cholesterol transporters in human macrophages. THP-1 macrophages were treated with Ad-
RIP140 or vector for 24 h and subjected to determine the mRNA (A) or protein (B) levels of SR-A, CD36, ABCA1, ABCG1 or GAPDH. Data are expressed as means ± S.E.M. (n = 4).
⁄P < 0.05, ⁄⁄P < 0.01 vs. Ad-GFP group. (C) THP-1 macrophages were incubated with oxLDL in the presence or absence of Ad-RIP140. Protein levels of ABCA1/G1 or a-tubulin
were determined. Data are means ± S.E.M. (n = 3). ⁄P < 0.05 vs. control. ##P < 0.01 vs. oxLDL treated group.
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of metabolic diseases because of its increasing level in macro-
phages following a high-fat-diet [21]. The current study aimed to
test the hypothesis that RIP140 is involved in the formation of
macrophage foam cells, a crucial step in the development of ath-
erosclerosis. We found the mRNA and protein levels of RIP140
were signiﬁcantly upregulated following oxLDL treatment in mac-
rophages (Fig. 1). Furthermore, a novel impact of RIP140 on oxLDL-
induced formation of macrophage foam cells was identiﬁed by pro-
moting cholesterol accumulation (Fig. 2). These ﬁndings support
our hypothesis and reveal that the upregulated RIP140 aggravates
cholesterol accumulation resulting to foam cell formation.
The intracellular cholesterol homeostasis in macrophages is
dynamically modulated by cholesterol uptake and cholesterol
efﬂux, which are tightly controlled by scavenger receptors and
reverse cholesterol transporters, respectively [4]. Uptake of choles-
terol occurs via the binding and uptake of native or modiﬁed lipo-
proteins by multiple macrophage scavenger receptors. The
constitutive nature of SR-A expression and the feed-forward regu-
lation of CD36 in macrophages lead to unregulated uptake of mod-
iﬁed LDL and cholesterol accumulation [6]. However, our data
showed that overexpressing RIP140 did not affect the expression
of SR-A or CD36 in human THP-1-derived macrophages (Fig. 3A
and B). Thus the effect of RIP140 on cholesterol uptake could be
excluded.Cholesterol efﬂux, the initial step of the revers cholesterol
transport (RCT) system, is also a homeostatic process with great
potential to affect atherosclerosis risk [22]. The ATP-binding cas-
sette transporters A1 and G1 (ABCA1/G1) are responsible for the
major part of macrophage cholesterol efﬂux to serum or HDL in
macrophage foam cells [23]. In the current study, we observed that
the mRNA and protein expressions of ABCA1/G1 were negatively
regulated by RIP140 (Fig. 3). ABCA1 is responsible for cholesterol
efﬂux to lipid-free apoA-I in macrophages [24]. In contrast, ABCG1
promotes macrophage efﬂux to mature HDL particles, but not to
lipid-free apolipoproteins [25], facilitating an alternative choles-
terol efﬂux pathway from macrophages [11]. Our observations
demonstrate that the downregulation of ABCA1/G1 by RIP140 lead
to the reduction of cholesterol efﬂux both ApoAI- and HDL-medi-
ated (Fig. 2D and E). Therefore, the present research indicates that
RIP140 overexpression reduces cholesterol efﬂux through ABCA1/
G1, accelerating oxLDL-induced foam cell formation, contributing
to aggravate atherosclerosis. These observations are in line with
the ﬁndings that mice lack of ABCA1/G1 expression in macro-
phages develop accelerated atherosclerosis [23].
To gain further insight into the mechanisms of RIP140 on
ABCA1/G1 expression, we next examined the functions of LXR in
the presence of RIP140. LXR is a major transcription factor for
genes important in cholesterol metabolism in response to cellular
cholesterol levels [26], and has been deﬁned as the master
Fig. 4. Repression of ABCA1/G1 expression is LXRE-dependent. (A) THP-1 macrophages were infected with Ad-RIP140 for 24 h, followed by treating with T0901317 (1 lM).
Nuclear extracts were isolated and subjected to western blotting to determine the protein levels of LXRa, LXRb and Histone H1. Data are means ± S.E.M. (n = 3). ⁄P < 0.05,
⁄⁄P < 0.01 vs. control group. ##P < 0.01 vs. T0901317 treated group. (B) Immunoprecipitation analysis were applied to detect the interaction between RIP140 and LXR. (C and
D) Dual luciferase reporter assays were performed to evaluate the inﬂuence of Ad-RIP140 on LXRE-dependent transcriptional activity. Data are expressed as means ± S.E.M.
(n = 3). ⁄P < 0.05 vs. control group. ##P < 0.01 vs. T0901317 treated group. (E) THP-1 macrophages were infected with Ad-RIP140 for 24 h and then treated with T0901317 or
vehicle for 12 h. Western blot were performed to determine protein levels of ABCA1/G1 or a-tubulin. Data are means ± S.E.M. (n = 3). ⁄⁄P < 0.01 vs. control group. ##P < 0.01 vs.
T0901317 treated group.
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mice have tissue lipid accumulation, including within macro-
phages, and increased atherosclerosis [27]. In this study, we dem-
onstrated that RIP140 signiﬁcantly reduced LXRa protein
expression in cell nuclei (Fig. 4A), and inhibited LXR transcriptional
activity (Fig. 4C and D). The activation of LXR by its synthetic ago-
nist T0901317 could induce expression of ABCA1/G1 in human
macrophages in a dose- and time-dependent manner (Supplemen-
tary Fig. 1). RIP140 abrogated this agonist function on upregulating
ABCA1/G1 expression. Taken all together, our data suggest that
RIP140 decreases cholesterol efﬂux via a LXR-ABCA1/G1 pathway.
In other words, RIP140 is a corepressor with LXR in ABCA1/G1
expression.
Nevertheless, RIP140 seems to function primarily as a scaffold
for the formation of different corepressor complexes. It is reported
that RIP140-mediated recruitment of DNA Methyltransferases
(Dnmts), histone deacetylases (HDACs), C-terminal binding pro-
teins (CtBPs) leads to histone and DNA methylation, ultimately
suppression of gene expression [28–30]. Thus, repressive activity
of RIP140 in regulating ABCA1/G1 expression might be this way.
Interestingly, RIP140 not only suppressed the activity of LXR,
but also decreased its expression. Nevertheless, it remains unclear
how RIP140 modulates LXRa expression. The expression of LXRa is
regulated by peroxisome proliferator-activated receptors (PPARs)[31,32], as well as an auto-regulatory mechanism [33]. It has been
proved that RIP140 is able to interact with both PPARs and LXR
[14,34,35]. Meanwhile there are functional cross-talks among
these nuclear receptors [36–38]. These suggest a complicate inter-
action among RIP140, PPARs and LXR. Intriguingly, RIP140 had no
signiﬁcant impact on LXRa mRNA expression (Supplementary
Fig. 2), which was not conformable with the change in protein
level. When in the presence of MG-132, a general proteasome
inhibitor, the protein level of LXRa was not affected by RIP140
overexpression (Supplementary Fig. 3), which indicated RIP140
may promote the degradation of endogenous protein. Therefore,
the post-translational regulation might be a potential mechanism
underlying the effect of RIP140 on LXRa expression. The prelimin-
ary results do not permit further speculation on the underlying
mechanisms.
In conclusion, our study demonstrates that RIP140 augments
the formation of macrophage foam cells by inhibiting ABCA1/G1-
mediated cholesterol efﬂux via suppressing LXR. These ﬁndings
shed lights on the important role of RIP140 in foam cell formation.
It should be noted that the current investigation was mainly per-
formed in macrophages in vitro. The in vivo function of RIP140 in
pathogenesis of atherosclerosis needs further investigations.
Therapeutic approaches targeting on RIP140 may provide novel
strategies for the treatment of atherosclerosis.
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